This company listing is no longer active
Akumin Past Earnings Performance
Past criteria checks 0/6
Akumin's earnings have been declining at an average annual rate of -72.8%, while the Healthcare industry saw earnings declining at 6.7% annually. Revenues have been growing at an average rate of 35.2% per year.
Key information
-72.79%
Earnings growth rate
-70.27%
EPS growth rate
| Healthcare Industry Growth | -6.74% |
| Revenue growth rate | 35.16% |
| Return on equity | n/a |
| Net Margin | -34.68% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Is Akumin (TSE:AKU) Using Too Much Debt?
Apr 06
Akumin (TSE:AKU) Has A Somewhat Strained Balance Sheet
Jan 06Akumin Inc.'s (TSE:AKU) Intrinsic Value Is Potentially 83% Above Its Share Price
Oct 05Is Akumin (TSE:AKU) Using Too Much Debt?
Sep 02Akumin (TSE:AKU) Use Of Debt Could Be Considered Risky
May 08A Look At The Fair Value Of Akumin Inc. (TSE:AKU)
Feb 05Akumin (TSE:AKU) Use Of Debt Could Be Considered Risky
May 14Will The ROCE Trend At Akumin (TSE:AKU) Continue?
Mar 02Is Akumin (TSE:AKU) Using Too Much Debt?
Feb 04
Could The Akumin Inc. (TSE:AKU) Ownership Structure Tell Us Something Useful?
Jan 13Have Insiders Been Selling Akumin Inc. (TSE:AKU) Shares This Year?
Dec 23Will Akumin's (TSE:AKU) Growth In ROCE Persist?
Dec 02Should You Be Concerned About Akumin Inc.'s (TSE:AKU) ROE?
Jul 28Would Shareholders Who Purchased Akumin's(TSE:AKU) Stock Year Be Happy With The Share price Today?
Jul 10Does Akumin's (TSE:AKU) Statutory Profit Adequately Reflect Its Underlying Profit?
Jun 22Revenue & Expenses Breakdown
How Akumin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 738 | -256 | 52 | 0 |
| 30 Jun 23 | 744 | -227 | 51 | 0 |
| 31 Mar 23 | 751 | -161 | 51 | 0 |
| 31 Dec 22 | 750 | -157 | 52 | 0 |
| 30 Sep 22 | 744 | -147 | 33 | 0 |
| 30 Jun 22 | 666 | -94 | 36 | 0 |
| 31 Mar 22 | 543 | -71 | 30 | 0 |
| 31 Dec 21 | 421 | -43 | 35 | 0 |
| 30 Sep 21 | 309 | -30 | 8 | 0 |
| 30 Jun 21 | 264 | -36 | 14 | 0 |
| 31 Mar 21 | 242 | -37 | 27 | 0 |
| 31 Dec 20 | 246 | -37 | 27 | 0 |
| 30 Sep 20 | 256 | -15 | 28 | 0 |
| 30 Jun 20 | 261 | -5 | 28 | 0 |
| 31 Mar 20 | 267 | 4 | 31 | 0 |
| 31 Dec 19 | 247 | 9 | 25 | 0 |
| 30 Sep 19 | 216 | 8 | 34 | 0 |
| 30 Jun 19 | 186 | 6 | 42 | 0 |
| 31 Mar 19 | 169 | 7 | 45 | 0 |
| 31 Dec 18 | 155 | 5 | 57 | 0 |
| 30 Sep 18 | 144 | 5 | 52 | 0 |
| 30 Jun 18 | 129 | -5 | 50 | 0 |
| 31 Mar 18 | 109 | -6 | 43 | 0 |
| 31 Dec 17 | 90 | -8 | 36 | 0 |
| 30 Jun 17 | 62 | -4 | 28 | 0 |
| 30 Sep 16 | 46 | -2 | 20 | 0 |
| 30 Sep 15 | 35 | -3 | 17 | 0 |
Quality Earnings: AKU is currently unprofitable.
Growing Profit Margin: AKU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKU is unprofitable, and losses have increased over the past 5 years at a rate of 72.8% per year.
Accelerating Growth: Unable to compare AKU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKU is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-5.9%).
Return on Equity
High ROE: AKU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/04 03:40 |
| End of Day Share Price | 2024/02/02 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akumin Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Noel Atkinson | Clarus Securities Inc. |
| Kyle McPhee | Cormark Securities Inc. |